The synthetic vaccine platform technology of Generex Biotechnology Corp. has been presented at the first International Swine Flu Conference in Washington, DC.
Douglas M. Powell, PhD, director of immunobiology at Antigen Express, a wholly owned subsidiary of Generex, described the advantages of suppressing a pandemic virus by next generation vaccines, such as Generex’s synthetic platform, which can be mass-produced using existing technology, more quickly and at lower cost than egg-based vaccines. New synthetic vaccine technology could help prevent infection and easen the severity of H1N1 in humans.
Traditional egg-based vaccines take months to develop and rely on live virus, which always carries the risk of infecting rather than inoculating. Generex’s proprietary synthetic vaccine platform does not use live virus, but instead arranges peptides to create a “snapshot” of the virus that activates the body’s T-cells to fight off the foreign invader, completely eliminating any risk of infection.
Generex’s vaccine platform is already in various stage clinical trials for avian flu, as well as prostate, breast and ovarian cancers, melanomas, SARS and HIV/AIDS.
In addition to the company’s vaccine platform technology, Generex has developed a range of products based on their proprietary RapidMist platform technology for drug delivery through the inner lining of the mouth, ensuring that there is no deposit in the lungs. The company’s flagship product, Generex Oral-lyn is an oral insulin spray product for the treatment of Type-1 and Type-2 diabetes, available to patients in certain overseas markets and in Phase III global clinical trials. Generex has also developed and markets a variety of over-the-counter products.
If you would like to make a comment, please fill out the form below.
Featured Reports
